SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,281. The last known price of Bitcoin is 71,086.72423286 USD and is down -3.89 over the last 24 hours. It is currently trading on 12779 active market(s) with $28,515,435,687.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins steep selloff is driving attention, with traders pointing to leveraged long liquidations and broader risk-off pressure. The community is split between buying an oversold dip near technical support and expecting further declines if selling continues.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Phase 3 REGAL trial of GPS has reached the 80th event, and the company expects topline results this month, driving intense attention ahead of the AML data readout. Traders celebrated a sharp after-hours move and speculated about a data leak or short covering, while others cautioned that the trial remains blinded and its outcome is unknown.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs decision to remove Strategy from its indexes is fueling concerns about passive fund selling, while Bitcoins decline adds pressure to the stock. Traders debate whether the potential outflows are already priced in and whether the exclusion will materially weaken Strategys Bitcoin-linked financing model.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

A widespread Microsoft 365 outage disrupted Outlook, Teams, Copilot and other services, prompting complaints from users whose work was interrupted. Traders debated whether the prolonged disruption should pressure the stock, which held near flat-to-positive, while some speculated about a cyberattack without confirmation.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.03439229 USD and is down -2.16 over the last 24 hours. It is currently trading on 1895 active market(s) with $1,786,076,895.36 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is sliding alongside a broader crypto selloff, with traders pointing to risk-off sentiment, inflation and rate-hike concerns, and leveraged liquidations. The steep decline has sparked debate over whether support will hold or losses will deepen, while some holders are buying the dip and others cite stalled regulatory progress and weak demand as reasons for caution.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs resignation and Colette Kresss interim appointment have rattled NVDA shares, with traders also debating potential China chip-export scrutiny and the companys reliance on Huangs leadership. The community is split between buying the selloff on confidence in Nvidias AI business and avoiding the stock amid leadership and regulatory uncertainty.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,962,604.07029401. The last known price of Zcash is 956.58767703 USD and is down -2.92 over the last 24 hours. It is currently trading on 670 active market(s) with $828,877,374.43 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcashs sharp pullback after a major rally is dominating discussion, with traders debating whether it is a broader crypto-market correction and liquidation flush or a deeper breakdown. Some call the selloff an oversold buying opportunity, while bears point to lost support and continued selling.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels planned prostate-cancer BLA filing has been pushed to mid-2027 amid FDA discussions and assay refinement, prompting a sharp selloff and criticism of managements communication and credibility. Some traders see the delay as a manufacturing and regulatory hurdle rather than a problem with the clinical data, while others remain concerned about execution and the longer wait.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is under pressure alongside Bitcoins slide and broader weakness in crypto-linked stocks, with traders highlighting fresh lows and arguing over whether the selloff has further to run or the shares are forming a base. Some also point to COINs underperformance versus Bitcoin and concerns about trading activity, while a smaller group sees an oversold bounce opportunity.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BMNR is drawing attention amid weakness in Ethereum and broader crypto-linked stocks, with traders focused on its ETH-treasury exposure and the shares decline. The community is split between dip-buyers expecting a recovery and critics questioning Tom Lees strategy, company spending, transparency and buybacks.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Bessemer is swimming against the PE tide in Indian healthcare

… hospital chains and the broader healthcare provider sector. Central to Bessemer … cumulative PE investment in offline healthcare providers at $10.6 billion … such as Apollo Hospitals, Max Healthcare , Fortis Healthcare , Narayana Hrudayalaya, and others …

Narayana Hrudayalaya Forms Wholly Owned Subsidiary to Drive Northern India Expansion

Narayana Hrudayalaya Ltd. ( ($IN:NH) ) just unveiled an update. Narayana Hrudayalaya Ltd. has incorporated a new wholly owned subsidiary, Narayana ...

Brief Healthcare: ORMP: Advancing Clinical Activities and more

In this briefing: ORMP: Advancing Clinical Activities RVPH: Brilaroxazine Poster Presentations WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 Narayana Hrudayalaya: A Quarter of Record Performance and Strategic Expansion UltraGreen.ai IPO: High Growth and High Margins, Market Leader 1. ORMP: Advancing Clinical Activities ORMP is leveraging its strong balance sheet to invest in early stage companies, primarily focusing on the medical & biopharma space. ORMP has substantial liquidity as it both advances its oral drug delivery platform and pursues strategic opportunities, including strategic investments. The company received ~$27m on its Scilex investment in 3Q25, with the principal on the Scilex investment now fully repaid. 2. RVPH: Brilaroxazine Poster Presentations Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications. The candidates address multiple related mental disorders, rare diseases & other categories of un met need.

Brief Healthcare: RVPH: Brilaroxazine Poster Presentations and more

In this briefing: RVPH: Brilaroxazine Poster Presentations WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 Narayana Hrudayalaya: A Quarter of Record Performance and Strategic Expansion UltraGreen.ai IPO: High Growth and High Margins, Market Leader Monash IVF (MVF AU) Rejects Soul Patts/Genesis' Offer 1. RVPH: Brilaroxazine Poster Presentations Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications. The candidates address multiple related mental disorders, rare diseases & other categories of un met need. Reviva's lead indication in schizophrenia with brilaroxazine completed its Phase III RECOVER trial & may pursue future studies. 2. WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 Key takeaways from 3Q25 earnings release. Lu highlighted Ainos’ strong revenue momentum, up more than 4x Y/Y, driven almost entirely by the deployment of AI Nose in senior care programs.

Brief Healthcare: WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 and more

In this briefing: WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 Narayana Hrudayalaya: A Quarter of Record Performance and Strategic Expansion UltraGreen.ai IPO: High Growth and High Margins, Market Leader Monash IVF (MVF AU) Rejects Soul Patts/Genesis' Offer Madrigal Pharma: Inside the MAESTRO-NASH Breakthrough- How Weight Loss Supercharges Antifibrotic Effects! 1. WTR Small-Cap Spotlight Recap: AI Nose's Continuing Momentum in 2025 and What to Expect in 2026 Key takeaways from 3Q25 earnings release. Lu highlighted Ainos’ strong revenue momentum, up more than 4x Y/Y, driven almost entirely by the deployment of AI Nose in senior care programs. Lu noted that the reported revenue has yet to include any of the $2.1-million, three-year AI Nose subscription order from a semiconductor customer, signaling additional upside in the SmellTech platform’s revenue, the turnaround in gross margin to 82% YTD from negative last year, and Ainos’ cost management with cash operating expenses reduced by 15% YTD versus the previous year.

Narayana Hrudayalaya shares climb 10% as Q2 net profit rises 30% to Rs 258.3 crore

Narayana Hrudayalaya shares saw a significant jump following strong quarterly results. The healthcare chain reported robust growth in revenue and profit for the September quarter. Both Indian and Cayman Islands operations contributed to this impressive performance. The company's net profit and operating revenue increased substantially year-on-year. This positive financial update has boosted investor confidence.

Narayana Hrudayalaya share price jumps over 7% on strong Q2 results; India, Cayman revenues highest ever

Narayana Hrudayalaya's share price rose over 7% after reporting record revenue and profitability for Q2FY26, with a net profit surge of 29.6% to ₹258 crore. Consolidated operating revenue increased by 20.3% to ₹1643.8 crore, driven by strong performance in both India and Cayman businesses.

Hospitals Get Pricing Relief: Fortis, Apollo, Max Healthcare Gain After Government Revises Rates For Nearly 2,000 Procedures

Equity

The CGHS revamp addresses long-standing concerns from private hospitals that earlier packages were outdated and failed to reflect rising medical costs

Narayana Hrudayalaya Faces Five Technical Red Flags: SEBI RA Warns Of An Overstretched Rally 

The stock has surged nearly 65% in 2025, but the analyst highlights a buildup of risk factors that could trigger a near-term correction.

Healthcare firm Narayana Hrudayalaya acquires prime land parcels in Bengaluru for ₹246 crore

Healthcare company Narayana Hrudayalaya Limited has … to documents accessed by Propstack. Healthcare company Narayana Hrudayalaya Limited has … along Bannerghatta Road, a prominent healthcare and residential corridor in south …

Narayana Hrudayalaya Ltd. engages in the provision of medical and health care services. It also provides services in the areas of cardiac surgery, cardiology, diabetes and endocrinology, gastroenterology, general surgery, neurosciences, facial surgery, nephrology, obstetrics and gynecology, orthopedics, oncology, pediatrics, transplant, urology, and vascular surgery; and other specialty services, such as dental, dermatology, emergency medicine, ears, nose, and throat, family medicine, general medicine, and genetic. The company was founded by Devi Prasad Shetty on July 19, 2000 and is headquartered in Bangalore, India.

Narayana Hrudayalaya Ltd

Neutral Sentiment

India’s healthcare services stocks rallied on Monday after the government announced the first major overhaul of the Central Government Health Scheme (CGHS) since 2014, revising rates for nearly 2,000 medical procedures. The new rates will come into effect from October 13.Shares of <a href="https://stocktwits.com/symbol/APOLLOHOSP.NSE">Apollo Hospitals</a> rose as much as 3.8%, <a href="https://stocktwits.com/symbol/MAXHEALTH.NSE">Max Healthcare</a> gained 4%, <a href="https://stocktwits.com/symbol/FORTIS.NSE">Fortis Healthcare</a> surged 4.8%, <a href="https://stocktwits.com/symbol/NH.NSE">Narayana Hrudayalaya</a> climbed 3.2% higher, and <a href="https://stocktwits.com/symbol/YATHARTH.NSE">Yatharh Hospital and Trauma Care</a> shot up 5% in morning trade.What Has Changed?Under the new structure, hospital charges will vary by accreditation status, city category, and ward entitlement.&nbsp; National Accreditation Board for Hospitals (NABH)-accredited facilities will serve as the base rate, while non-accredited hospitals will receive 15% lower rates. Additionally, treatment costs in tier 2 and tier 3 cities will be priced 10–20% below those in tier 1.The CGHS revamp addresses long-standing concerns from private hospitals that earlier packages were outdated and failed to reflect the rising costs of medical care. The move is expected to improve participation from private hospitals and ease patient access to cashless treatment.Impact On Medical ProceduresAccording to reports, DAM Capital estimates that the revised CGHS structure could result in an average increase of 25% - 30% across major medical procedures.Among listed hospital operators, Fortis, Max Healthcare, Narayana Health, and Yatharth Hospitals are expected to gain the most, given their higher exposure to government healthcare schemes, with Yatharth’s share estimated at around 35%.Other players such as Apollo Hospitals (9% exposure), Max Healthcare (21.8%), Global Health (18%), and Narayana Health (18%) are also likely to benefit from the revision.For updates and corrections, email newsroom[at]stocktwits[dot]com.

View of Fortis in Hospital in Delhi, India, on 29 January 2018. (Photo by Nasir Kachroo/NurPhoto via Getty Images)

Current Price	1,866.60
Prev Close	1,845.00
Open	1,840.70
Dividend Yield	0.28%
50-Day Moving Average	1,812.94
Beta	N/A
Avg. Volume	124,881.09
PE Ratio	43.52

52-Week High	2,093.30
52-Week Low	1,589.00
Market Capitalization	381.46B
EPS (Annual)	39.67
Price to Book	7.47
Revenue Per Employee	5.11M

Feed

News

Sentiment

Fundamentals

Info

NH.NSE Fundamentals